at CNBC.com (Dec 10, 2014)
Epizyme (EPZM +2.4%) trades higher after Wedbush's Greg Wade ramps up coverage with an Outperform rating and a $37 price target. Wade says that advances in genetically defining sub-sets of cancer patients have led to identifying certain histone methyltransferase proteins as key malignant drivers, and EPZM's small molecule drug discovery platform is key to marrying these antagonists with the genetically definable malignancy.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at CNBC.com (Dec 8, 2014)
at Zacks.com (Nov 21, 2014)
at CNBC.com (Apr 25, 2014)
at CNBC.com (Jan 7, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs